Intravitreal bevacizumab in central serous chorioretinopathy

Journal of the College of Physicians and Surgeons Pakistan

Volumn 22, Issue 6, 2012, Pages 363-366

  Jamil, Ahmad Zeeshan ^a   Rahman, Fawad Ur ^a   Iqbal, Kashif ^a   Ansari, Harris Muzammil ^a   Iqbal, Wasim ^a   Mirza, Khurram Azam ^a  

^a Layton Rahmatullah Benevolent Trust (LRBT)   (Pakistan)

Author keywords

Bevacizumab; Central serous chorioretinopathy; Intravitreal injection; Optical coherence tomography

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; OFF LABEL DRUG USE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT SELECTION; QUASI EXPERIMENTAL STUDY; TREATMENT OUTCOME; VISUAL ACUITY; WILCOXON SIGNED RANKS TEST;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84864415256     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jaun LX, Song JZ. intravitreal Bevacizumab injection for chronic central serous Chorioretinopathy. Chin Med J 2010; 123:2145-7.
2. Haimovici R, Koh S, Gangnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy. Ophthalmology 2004; 111:244-9.
3. Jampol LM, Weinreb R, Yannuzzi L. involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale of new treatment strategies. Ophthalmology 2002; 109:1765-6.
4. Gass JD, editor. Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed. St. Louis: Mosby; 1997.
5. Mehany SA, Shawkat AM, Sayed MF, Mourad KM. Role of Avastin in management of central serous chorioretinopathy. Saudi J Ophthalmol 2010; 24:69-75.
6. Stephen L, Perkins, Judy E, Kim, John S. Pollack, Pauline T. Clinical characteristics of central serous chorioretinopathy in women. Ophthalmology 2002; 109:262-6.
7. Tewari HK, Gadia R, Kumar D, Venkatesh P. Sympatheticparasympathetic activity and reactivity in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2006; 47:3474-8.
8. Guyer DR, Yannuzzi LA, Slakter JS. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112:1057-62.
9. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121:26-34.
10. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. intravitreal Bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19:613-7.
11. Jalk AE, Jabbour N, Avila MP. Pigment epithelium decompensation, clinical features and natural course. Ophthalmology 1984; 91:1544-8.
12. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137:1073-80.
13. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109:1723-5.
14. Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK. Fluorescene angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 2005; 25:422-9.
15. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104:616-22.
16. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23:235-7.
17. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 2006; 26:239-42.
18. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53:52-6.
19. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S. Penetration of Bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48:2814-3.
20. Gunther JB, Altaweel MM. Bevacizumab for the treatment of ocular disease. Surv Ophthalmol 2009; 54:372-400.
21. Niegel MF, Schrage NF, Christmann S, Degenering RF. Intravitreal Bevacizumab for chronic central serous chorioretinopathy. Ophthalmology 2008; 105:943-5.
22. Mazhar PS, Hanfi AN, Khan A. Angiogenesis and role of anti VEGF therapy. Pak J Ophthalmol 2009; 25:169-73.
23. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V. A pilot study of intravitreal Bevacizumab for the treatment of central serous chorioretinopathy. Graefe's Arch Clin Exp Ophthalmol 2008; 246: 1235-9. Epub 2008 Jun 4.